ArticleFrontiers in immunology2025
Postbiotic effects elicited by heat-inactivated
Article in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Immunonutritional effects elicited by a novel multicomponent food supplement in children with cow's milk allergy: results from a randomized, placebo-controlled trial.Frontiers in allergy · 2026Trial
- Postbiotics in Functional Foods: Preparation-Based Characterization, Gut-Brain Axis Interactions, and Translational Perspectives.Foods (Basel, Switzerland) · 2026Review
- New Postbiotic Derived from Sequential Fermentation of TwoMicroorganisms · 2026Article
- Novel Food Supplement Containing a Combination of Postbiotics and Plant-Derived Compounds Regulates Epithelial Barrier Integrity and Immune Response in Human Enterocytes.Foods (Basel, Switzerland) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The probiotic Methods: Peripheral blood mononuclear cells (PBMCs) collected from IgE-mediated CMA children (n=6, all Caucasian, mean age 31.2 months) were stimulated with beta-lactoglobulin (BLG) in the absence or presence of LGGp. Activated regulatory T cells (Tregs)number was assessed by flowcytometry. Growth factors and cytokines modulating interleukins (IL) production were assessed by RT-PCR. IL-4, 5, 13 and 10 production was assessed by ELISA. The LGGp effects on gut barrier were evaluated using a Caco-2 cells-based experimental model by measuring transepithelial electrical resistance (TEER); tight junction proteins, Mucin-2 (Muc-2), and lactase expression; and FITC dextran permeability. Results: LGGp exposure resulted in Tregs activation and beneficial modulation of cytokines production in PBMCs from CMA patients. These effects paralleled with beneficial effects on all biomarkers of gut barrier integrity. Conclusions: Our data suggest that LGGp, modulating several immune tolerance mechanisms, could be a promising therapeutic strategy against CMA.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.